Long-Term Complete Remission in an Acute Myeloid Leukemia Patient with Isolated Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
10.12701/yujm.2012.29.2.96
- Author:
Myung Jin KIM
1
;
Sung Ae KO
;
Hyo Jin JANG
;
Da Eun JEONG
;
Jeung Min PARK
;
Kyoung Hee LEE
;
Min Kyoung KIM
;
Young Kyung BAE
;
Myung Soo HYUN
Author Information
1. Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Korea. hms@med.yu.ac.kr
- Publication Type:Case Report
- Keywords:
Meningeal carcinomatosis;
Leukemia;
Central nervous system;
Bone marrow transplantation
- MeSH:
Adult;
Bone Marrow;
Bone Marrow Transplantation;
Central Nervous System;
Female;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Leukemia;
Leukemia, Myeloid, Acute;
Meningeal Carcinomatosis;
Prognosis;
Recurrence;
Skin;
Spine
- From:Yeungnam University Journal of Medicine
2012;29(2):96-101
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Allogeneic hematopoietic stem cell transplantation (HSCT) is considered the optimal curative treatment for acute myeloid leukemia (AML), but some patients develop bone marrow relapse due to remnant leukemia, and few patients develop extramedullary relapse without bone marrow relapse. Isolated extramedullary relapse (IMER) is defined as extramedullary relapse without bone marrow relapse. IMER has been reported in various sites, including the skin, soft tissue, and central nervous system(CNS). Isolated CNS relapse is relatively rare and is associated with poor prognosis due to the absence of an optimal treatment for it. Reported herein is a case involving an adult AML woman who suffered from isolated extramedullary relapse in the CNS after allogeneic HSCT. She was treated with intrathecal chemotherapy and whole-brain and spine radiotherapy, followed by systemic chemotherapy. She is currently well, with no evidence of leukemia recurrence for over six years.
